Shafaqna English– Nestle aims to leverage artificial intelligence and nutritional science to transform the growing popularity of GLP-1 weight-loss medications—which pose a threat to its traditional business—into a novel commercial opportunity. The company is currently developing products tailored to meet the needs of millions of consumers using drugs such as Ozempic and Wegovy.
The widespread embrace of drugs manufactured by Novo Nordisk and Eli Lilly has sparked investor worries that these appetite-suppressing medications could structurally and permanently dampen demand for packaged foods, snacks, and beverages.
Source: Reuters